文献速递肿瘤 PET/CT

新型异二聚体示踪剂68Ga-pentixafor-c(RGDfK)的合成、临床前评价及肿瘤PET-CT显像临床应用

Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-09

本研究合成并临床前评价了靶向CXCR4与整合素αvβ3的新型双靶点PET示踪剂68Ga-pentixafor-c(RGDfK),并在U87MG细胞与荷瘤小鼠中验证其亲和力与体内药代动力学。前瞻性分析显示,该示踪剂PET/CT诊断原发与转移灶的灵敏度、特异度及准确率均高于18F-FDG PET/CT(93.1% vs 74.7%、79.2% vs 62.5%、90.1% vs 72.1%;93.2% vs 74.5%、84.7% vs 78%、89.7% vs 75.9%)。120 min延迟扫描的肿瘤/本底比值(TBR)显著高于60 min(P < 0.05)。

要点

  • 68Ga-pentixafor-c(RGDfK)在U87MG细胞中摄取、靶向特异性及亲和力均高于68Ga-pentixafor。
  • 荷瘤小鼠中肿瘤摄取高于正常组织(P < 0.05),主要经肾脏排泄,肝胆排泄低。
  • 临床诊断原发与转移灶的灵敏度、特异度、准确率均高于18F-FDG PET/CT。

核心结论

  • 68Ga-pentixafor-c(RGDfK) PET/CT在肿瘤诊断中表现出良好的安全性和临床可行性,尤其在18F-FDG PET/CT结果不确定时有助于鉴别良恶性病变。

研究设计与样本

  • 体外实验在U87MG细胞中评估68Ga-pentixafor-c(RGDfK)对细胞活力、靶向特异性及亲和力的影响。
  • 在U87MG荷瘤BALB/c裸鼠中进行micro-PET/CT显像与生物分布研究以评价体内药代动力学。
  • 对同时接受68Ga-pentixafor-c(RGDfK) PET/CT与18F-FDG PET/CT的患者进行前瞻性分析,并比较两种显像结果。

主要发现

  • 体外实验中68Ga-pentixafor-c(RGDfK)在U87MG细胞中的摄取活性、靶向特异性及亲和力均高于68Ga-pentixafor。
  • 体内实验中肿瘤摄取高于正常组织(P < 0.05),主要经肾脏排泄,肝胆排泄低。
  • 68Ga-pentixafor-c(RGDfK) PET/CT诊断原发病灶的灵敏度93.1% vs 18F-FDG PET/CT 74.7%,特异度79.2% vs 62.5%,准确率90.1% vs 72.1%。
  • 68Ga-pentixafor-c(RGDfK) PET/CT诊断转移灶的灵敏度93.2% vs 18F-FDG PET/CT 74.5%,特异度84.7% vs 78%,准确率89.7% vs 75.9%。
  • 120 min延迟扫描的肿瘤/本底比值(TBR)显著高于60 min(P < 0.05)。

关键数值与推荐

  • 原发病灶诊断:68Ga-pentixafor-c(RGDfK) PET/CT灵敏度93.1%、特异度79.2%、准确率90.1%,18F-FDG PET/CT分别为74.7%、62.5%、72.1%。
  • 转移灶诊断:68Ga-pentixafor-c(RGDfK) PET/CT灵敏度93.2%、特异度84.7%、准确率89.7%,18F-FDG PET/CT分别为74.5%、78%、75.9%。
  • 肿瘤/本底比值(TBR):120 min延迟扫描显著高于60 min(P < 0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: CXCR4 and integrin αvβ3 play important roles in tumor biology and are highly expressed in multiple types of tumors. This study aimed to synthesize, preclinically evaluate, and clinically validate a novel dual-targeted PET imaging probe 68Ga-pentixafor-c(RGDfK) for its potential in imaging tumors. METHODS: The effects of 68Ga-pentixafor-c(RGDfK) on cell viability, targeting specificity, and affinity were assessed in the U87MG cells. Micro-PET/CT imaging and biodistribution studies were conducted in U87MG tumor-bearing BALB/c nude mice to evaluate the probe's in vivo pharmacokinetics. A prospective analysis was conducted on patients who underwent both 68Ga-pentixafor-c(RGDfK) PET/CT and 18F-FDG PET/CT. The results obtained from the two imaging modalities were compared. RESULTS: In vitro, 68Ga-pentixafor-c(RGDfK) showed higher uptake activity, targeting specificity, and affinity in U87MG cells than 68Ga-pentixafor. In vivo, tumor uptake was higher than in normal tissues (P < 0.05), with renal excretion and low hepatobiliary excretion. Clinical results indicated that 68Ga-pentixafor-c(RGDfK) PET/CT had higher sensitivity, specificity, and accuracy in diagnosing primary and metastatic lesions compared to 18F-FDG PET/CT (93.1% vs. 74.7%, 79.2% vs. 62.5%, 90.1% vs. 72.1%, and 93.2% vs. 74.5%, 84.7% vs. 78%, 89.7% vs. 75.9%). The tumor-to-background ratio (TBR) at 120 min delayed scanning was significantly higher than at 60 min (P < 0.05). CONCLUSION: 68Ga-pentixafor-c(RGDfK) PET/CT demonstrated good safety and clinical feasibility in diagnosing tumors, particularly in differentiating benign and malignant lesions when 18F-FDG PET/CT results are uncertain.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jia F, Hou D, Zhang H, et al. Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer 68Ga-pentixafor-c(RGDfK) for PET-CT imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 40924150. doi:10.1007/s00259-025-07549-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。